CD22-targeted CAR-T immunotherapy

DRUG CLASS:

News alerts, weekly reports and conference planners

MYC translocation	Non-Hodgkin’s Lymphoma	MYC translocation	Non-Hodgkin’s Lymphoma	CAR-T19/CAR-T22 immunotherapy Sensitive: C3 – Early Trials CAR-T19 / CAR-T22 immunotherapy Sensitive : C3	CAR-T19/CAR-T22 immunotherapy Sensitive: C3 – Early Trials CAR-T19 / CAR-T22 immunotherapy Sensitive : C3
TP53 mutation	Lymphoma	TP53 mutation	Lymphoma	CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy Sensitive : C3	CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy Sensitive : C3
CD22 expression	B Acute Lymphoblastic Leukemia	CD22 expression	B Acute Lymphoblastic Leukemia	CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy Sensitive : C3	CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials CD19-targeted CAR-T immunotherapy + CD22-targeted CAR-T immunotherapy Sensitive : C3

Associations(3)